...
首页> 外文期刊>Genetic testing and molecular biomarkers >Letter to the Editor Central Retinal Vein Occlusion Secondary to Clomiphene Treatment in a Male Carrier of Factor V Leiden
【24h】

Letter to the Editor Central Retinal Vein Occlusion Secondary to Clomiphene Treatment in a Male Carrier of Factor V Leiden

机译:写给编辑视网膜中央静脉在阻塞继发于克罗米酚治疗男性的载体因子V莱顿

获取原文
获取原文并翻译 | 示例
           

摘要

We report a case of a 35-year-old previously healthy man treated with clomiphene for infertility, who presented with blurred vision in his left eye due to ocular vein occlusion as documented by fluorescein angiography. The patient was heterozygous for the factor V Leiden (FV Leiden) mutation and for the 1298 A-C polymorphism of the methylene-tetrahydrofolate reductase (MTHFR) gene. He was treated with clopidogrel and is now free of symptoms. Because congenital thrombophilia is a moderate risk factor for central retinal vein occlusion and the administration of clomiphene may trigger this process, we recommend screening of young patients for FV Leiden before clomiphene treatment.
机译:我们报告一位35岁之前健康的人与克罗米酚治疗不孕不育,出现视力模糊左眼因眼静脉阻塞通过荧光素造影记录。病人是V莱顿的杂合的因素(阵线莱顿)突变和1298 a - c多态性的中还原酶(MTHFR)基因。氯吡格雷,现在免费的症状。先天性血栓形成倾向是一个温和的风险视网膜中央静脉阻塞和因素克罗米酚可能会触发管理的过程,我们建议筛查的年轻患者之前的阵线莱顿克罗米酚治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号